Univariate analysis of the association between clinical characteristics and survival outcomes for all patients with early-stage NKTCL
| . | . | 5-y OS . | . | 5-y PFS . | . |
|---|---|---|---|---|---|
| Characteristic . | No. (%) . | % (95% CI) . | P . | % (95% CI) . | P . |
| Sex | .373 | .811 | |||
| Male | 882 (69.3) | 62.4 (58.5-66.1) | 54.1 (50.4-57.8) | ||
| Female | 391 (30.7) | 66.6 (60.9-71.6) | 55.8 (50.1-61.1) | ||
| Age (y) | <.001 | .022 | |||
| ≤60 | 1099 (86.3) | 65.4 (62.0-68.6) | 55.5 (52.2-58.8) | ||
| >60 | 174 (13.7) | 52.7 (43.4-61.2) | 48.7 (39.8-56.9) | ||
| B symptoms | .160 | .019 | |||
| Yes | 509 (40.0) | 60.9 (55.0-65.4) | 50.6 (53.2-61.0) | ||
| No | 764 (60.0) | 65.5 (61.4-69.2) | 57.2 (44.7-57.5) | ||
| Elevated LDH | <.001 | <.001 | |||
| Yes | 403 (31.7) | 55.9 (50.2-61.2) | 48.7 (43.4-53.9) | ||
| No | 870 (68.3) | 67.7 (63.9-71.2) | 57.4 (53.5-61.1) | ||
| ECOG PS | <.001 | <.001 | |||
| 0-1 | 1202 (94.4) | 65.4 (62.2-68.5) | 56.3 (53.1-59.4) | ||
| ≥2 | 71 (5.6) | 36.6 (24.3-48.9) | 28.0 (17.3-39.6) | ||
| Primary location | .907 | <.001 | |||
| UADT | 1260 (99.0) | 63.7 (60.5-66.7) | 55.1 (52.0-58.2) | ||
| Extra-UADT | 13 (1.0) | 68.2 (29.7-88.6) | 0 | ||
| Ann Arbor stage | <.001 | <.001 | |||
| I | 947 (74.4) | 67.6 (64.0-71.0) | 58.3 (54.6-61.7) | ||
| II | 326 (25.6) | 51.3 (44.7-57.5) | 44.0 (37.8-50.1) | ||
| PTI | <.001 | <.001 | |||
| Yes | 689 (54.1) | 53.0 (48.4-57.4) | 45.2 (40.9-49.4) | ||
| No | 584 (45.9) | 75.9 (71.7-79.6) | 65.6 (61.1-69.7) | ||
| Risk group | <.001 | <.001 | |||
| Low | 298 (23.4) | 86.6 (81.5-90.3) | 73.3 (66.9-78.6) | ||
| High | 975 (76.6) | 56.9 (53.3-60.6) | 49.3 (46.6-53.8) |
| . | . | 5-y OS . | . | 5-y PFS . | . |
|---|---|---|---|---|---|
| Characteristic . | No. (%) . | % (95% CI) . | P . | % (95% CI) . | P . |
| Sex | .373 | .811 | |||
| Male | 882 (69.3) | 62.4 (58.5-66.1) | 54.1 (50.4-57.8) | ||
| Female | 391 (30.7) | 66.6 (60.9-71.6) | 55.8 (50.1-61.1) | ||
| Age (y) | <.001 | .022 | |||
| ≤60 | 1099 (86.3) | 65.4 (62.0-68.6) | 55.5 (52.2-58.8) | ||
| >60 | 174 (13.7) | 52.7 (43.4-61.2) | 48.7 (39.8-56.9) | ||
| B symptoms | .160 | .019 | |||
| Yes | 509 (40.0) | 60.9 (55.0-65.4) | 50.6 (53.2-61.0) | ||
| No | 764 (60.0) | 65.5 (61.4-69.2) | 57.2 (44.7-57.5) | ||
| Elevated LDH | <.001 | <.001 | |||
| Yes | 403 (31.7) | 55.9 (50.2-61.2) | 48.7 (43.4-53.9) | ||
| No | 870 (68.3) | 67.7 (63.9-71.2) | 57.4 (53.5-61.1) | ||
| ECOG PS | <.001 | <.001 | |||
| 0-1 | 1202 (94.4) | 65.4 (62.2-68.5) | 56.3 (53.1-59.4) | ||
| ≥2 | 71 (5.6) | 36.6 (24.3-48.9) | 28.0 (17.3-39.6) | ||
| Primary location | .907 | <.001 | |||
| UADT | 1260 (99.0) | 63.7 (60.5-66.7) | 55.1 (52.0-58.2) | ||
| Extra-UADT | 13 (1.0) | 68.2 (29.7-88.6) | 0 | ||
| Ann Arbor stage | <.001 | <.001 | |||
| I | 947 (74.4) | 67.6 (64.0-71.0) | 58.3 (54.6-61.7) | ||
| II | 326 (25.6) | 51.3 (44.7-57.5) | 44.0 (37.8-50.1) | ||
| PTI | <.001 | <.001 | |||
| Yes | 689 (54.1) | 53.0 (48.4-57.4) | 45.2 (40.9-49.4) | ||
| No | 584 (45.9) | 75.9 (71.7-79.6) | 65.6 (61.1-69.7) | ||
| Risk group | <.001 | <.001 | |||
| Low | 298 (23.4) | 86.6 (81.5-90.3) | 73.3 (66.9-78.6) | ||
| High | 975 (76.6) | 56.9 (53.3-60.6) | 49.3 (46.6-53.8) |
CI, confidence interval.